Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home About Us
In the News

August 22, 2014
Bioniche Life Sciences Announces Terms of $5 Million Financing & Use of Proceeds

August 21, 2014
Bioniche Life Sciences Announces Overnight Marketed Offering


Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Board of Directors

Board Mandate and Governance Guidelines

The composition of the Board of Directors reflects the Company's intent to have a majority of non-management Directors.

All Directors have a competence that contributes to the development of operating plans put forward by the company's management.


Dr. Michael BerendtDr. Michael Berendt
Chief Executive Officer & Chief Scientist

Appointed November 1, 2013

Dr. Michael Berendt held positions of increasing responsibility in the U.S. research departments of Pfizer, Inc. and Bayer Corporation before becoming Managing Director, Life Sciences Sector of AEA Investors, then Managing Director of Research Corporation Technologies. In 2006, he became the President & CEO of Aegera, which was sold to Pharmascience in 2011. Dr. Berendt graduated with a B.S. from Ohio Dominican University, a M.S. from Miami University, and a Ph.D. in Medical Microbiology and Immunology from Drexel University. Dr. Berendt is a Director on the Boards of Waters Corporation and NeoMed Institute. He serves as Executive Chairman of Anchor Therapeutics and serves as Chairman of Alethia Biothérapeutiques.

Dr. Berendt brings to the Company:

  • Leadership acumen in human therapeutics research and development;
  • A network of contacts in the North American life sciences investment sector; and
  • Knowledge of human pharmaceutical life cycle management.

Director Biographies

Mr. James Rae – Chairman and Non-Executive Director  (Independent)

Appointed July 27, 2012

James RaeMr. James Rae has been the CEO of London, Ontario-based Viron Therapeutics Inc. since 2007. He has considerable experience in financing from public, private and government sectors and in deal-making with multinational companies. Following 18 years at pharmaceutical company, Searle, latterly as CEO, he was President and CEO of Cangene, a publicly-listed biotech company where he was responsible for restructuring and orchestrating a reverse takeover of the company at a significant multiple. Mr. Rae was previously Chairman and CEO of Vaxis Therapeutics in Kingston, Ontario, Chairman and CEO of Resolution Pharma in Toronto, Ontario and, more recently, CEO of Cytochroma Inc., a Markham, Ontario-based biotech company which he transitioned from a research entity into one advanced in clinical development with a diversified product base. Mr. Rae was most recently the Chairman of Montreal-based Aegera Therapeutics, which was acquired by Pharmascience Inc. in late 2011. He presently holds directorships in three Canadian biotech companies and has previous experience as a Director on the Boards of a number of publicly-traded biotechnology companies.

Mr. Rae brings to the Company:

  • a wealth of experience in both governance and management roles in the biopharmaceutical sector;
  • manufacturing, marketing, financial and research and development experience in pharmaceutical and biotechnology firms;
  • financing and deal-making expertise; and
  • extensive network of contacts – inside and outside the sector.


Mr. Yvon Bastien – Chairman and Non-Executive Director  (Independent)

Appointed November 5, 2013

Yvon BastienMr. Yvon Bastien has served in pharmaceutical sales, marketing and leadership positions throughout his career, most recently serving as President and General Manager of Sanofi Synthelabo based in Markham, Ontario, Canada. Prior to joining Sanofi, Mr. Bastien was Founder and President of Delta Healthcare, an early stage biotechnology company based in Canada. Prior to Delta, Mr. Bastien served as President of Montreal, Quebec-based Jouveinal, European Marketing Manager of Ciba Geigy (Switzerland), Vice-President, International Marketing and Sales of Laboratoire Debat in Paris, France, General Manager of IMS Canada (Montreal), and Hospital Sales Representative with Ely Lilly (Montreal). Mr. Bastien trained in medicine at Louvain University in Belgium before completing an MBA at Sir George William University in Montreal and an Executive Management Program in France. He serves on the Board of Directors of four companies (including Bioniche) in the fields of biotechnology and health care, and holds the position of Chairman for two of these companies.

Mr. Bastien brings to the Company:

  • Extensive experience in human pharmaceutical sales and marketing, including successful product launches;
  • Negotiating skills in the areas of pharmaceutical reimbursement, product acquisitions, and licensing agreements;
  • Extensive experience as CEO of Canadian pharmaceutical companies; and
  • Governance experience relevant to the life sciences sector.



Mr. Rod Budd – Non-Executive Director (Independent)

Appointed November 9, 2011

Rod BuddMr. Rod Budd was a partner in Ernst & Young for 25 years until his retirement in 2010. For the last eight years of his term, he was the Canadian firm’s life sciences practice leader. Mr. Budd graduated from Concordia University in 1974 with a Bachelor of Commerce in accounting and finance and obtained his CA in 1977 (in Québec and Ontario). He has over 35 years of experience in public accounting, serving emerging and growth companies, with a focus on life sciences companies, from start-ups to large multinationals. Mr. Budd advises a number of private companies, Board and chairs the Audit Committee of Immunotec Inc.

Mr. Budd brings to the Company:

  • broad financial acumen; ability to review and understand financial statements and reports, budgets, forecasts and other financial information from the perspective of a financial professional;
  • audit experience; ability to review auditors’ plans, activities and reports and ensure they are meeting professional standards and corporate requirements;
  • extensive knowledge of the life sciences industry; awareness of industry trends; and
  • extensive experience working with Boards of Directors of public companies.


Ms. Lyne Fortin – Non-Executive Director (Independent)

Appointed November 5, 2013

Lyne FortinLyne Fortin has been in Executive level positions at Merck Canada for 13 years until 2011. In these roles she was responsible for Marketing and Sales of product portfolios in diverse therapeutic areas. She also managed all the commercial support functions which included marketing and sales research, sales training, sales operations, manufacturing planning, Office of Compliance, Sigma and change management. From 2005 to 2009, she was appointed to the Merck Marketing Committee for Europe, Middle-East, Africa and Canada to advance commercial practices and became a member of the Board of Directors of Merck Canada in 2007 until 2011.

Ms Fortin graduated from University of Montréal with a Certificate in Chemistry in 1978 and a Bachelor degree in Pharmacy in 1982 (Member of the Order of Pharmacists of Québec from 1983-2012). She obtained a MBA from Concordia University in 1984.

She has over 27 years of experience in the commercialization of pharmaceutical products for Human health which included working in the U.S. managing sales for the entire portfolio of promoted products for Merck USA in the Southern California Region. Over those years she was involved in multiple business development initiatives, ranging from licensing in and out, to co-promotion, joint venture and merger agreements. More recently Ms. Fortin has acted as Consultant to the biopharmaceutical industry advising clients on commercial matters.


Mr. Gregory Gubitz – Non-Executive Director (Independent)

Appointed September 12, 2013

Mr. Gregory Gubitz is an independent advisor to various life science companies and private equity firms. He also serves as Director on the Board of biOasis Technologies and is Chair of Big Life Foundation Canada. Mr. Gubitz served as Senior Vice President, Corporate Development and General Counsel of Biovail Corporation, Canada’s largest publicly traded pharmaceutical company. In that capacity, he was responsible for M&A and product acquisitions for global legal operations, culminating in the very successful $7B merger of Biovail and Valeant International. Prior to Biovail, Mr. Gubitz spend 10 years with MDS Capital, a leading North American venture capital company focused on healthcare. As COO of MDS, Mr. Gubitz was responsible for nine public and private venture funds, 20 investment professionals and $1B under management. Prior to MDS, Mr. Gubitz was a partner at one of Canada’s leading international law firms. Mr. Gubitz graduated from McGill University with Great Distinction and was called to the Ontario Bar in 1984.

Mr. Gubitz brings to the Company:

  • legal acumen;
  • experience in healthcare M&A;
  • financial markets expertise; and
  • an extensive network of healthcare and venture capital contacts.


Board Committee Charters


Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy